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A B S T R A C T
Purpose
We investigated the impact of Hodgkin lymphoma (HL) on parenthood, including factors
influencing parenthood probability, by comparing long-term HL survivors with matched general
population controls.
Patients and Methods
A Life Situation Questionnaire was sent to 3,604 survivors treated from 1964 to 2004 in successive
clinical trials. Responders were matched with controls (1:3 or 4) for sex, country, education, and year
of birth (10-year groups). Controls were given an artificial date of start of treatment equal to that of their
matched case. The main end point was presence of biologic children after treatment, which was
evaluated by using conditional logistic regression analysis. Logistic regression analysis was used to
analyze factors influencing spontaneous post-treatment parenthood.
Results
In all, 1,654 French and Dutch survivors were matched with 6,414 controls. Median follow-up was
14 years (range, 5 to 44 years). After treatment, the odds ratio (OR) for having children was 0.77
(95% CI, 0.68 to 0.87; P  .001) for survivors compared with controls. Of 898 survivors who were
childless before treatment, 46.7% achieved post-treatment parenthood compared with 49.3% of
3,196 childless controls (OR, 0.87; P  .08). Among 756 survivors with children before treatment,
12.4% became parents after HL treatment compared with 22.2% of 3,218 controls with children
before treatment (OR, 0.49; P  .001). Treatment with alkylating agents, second-line therapy, and
age older than 35 years at treatment appeared to reduce the chances of spontaneous post-
treatment parenthood.
Conclusion
Survivors of HL had slightly but significantly fewer children after treatment than matched general
population controls. The difference concerned only survivors who had children before treatment
and appears to have more personal than biologic reasons. The chance of successful post-
treatment parenthood was 76%.
J Clin Oncol 30:3854-3863. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Hodgkin lymphoma (HL) has high cure rates (80%
to 90%) and a predominant incidence in patients
age 20 to 44 years. Many patients wish to start or
complete a family after therapy.1-3 There are few
studies on parenthood after treatment specifically
for HL, and most concern outdated treatment
regimens4 and/or small patient groups.5,6 Publi-
cations on mixed cancer types often concern sur-
vivors of childhood cancer,7,8 do not take into
account whether patients attempted parenthood,9-12
or lack a suitable general population compari-
son group.4,6,13
Since 1964, the EuropeanOrganisation for Re-
search and Treatment of Cancer (EORTC) Lym-
phoma Group, along with the Groupe d’Etude des
Lymphomes de l’Adulte [GELA] since 1993, has uni-
formly treated patients with HL in successive clinical
trials. From1982onward, these trials focusednot only
on efficacy but also on reduction of treatment-related
toxicity. In 2009, a Life SituationQuestionnaire (LSQ)
with questions related to fertility and parenthood,
amongothers, was sent to patients.
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We investigated the influence of treatment for HL on successful
motherhood and fatherhood in a large cohort of European long-term
survivors, comparing HL survivors with matched general population
controls. We also investigated factors influencing the success of at-
tempted parenthood by comparing different treatment regimens in a
nested case-control study.
PATIENTS AND METHODS
Survivors
Overall, 6,658 patients with histologically proven, newly diagnosed HL
were included in nine consecutive randomized trials between 1964 and 2004
(Table 1). For detailed protocols of these trials, see Raemaekers et al,2 Tubiana
Table 1. Case and Control Characteristics (males and females, external and internal analyses)
Characteristic
Controls Cases
Matched Controls
External Analysis
Included in
External Analysis
Included in Internal
Analysis†
All Patients Included
in H1-H9 Trials
No. % No. % No. % No. %
Cases 6,414 1,654 25 745 11 6,658
Males 3,166 49 815 49 345 46 3,638 55
Country
France 2,862 45 737 45 285 38 2,991 45
Netherlands 3,552 55 917 55 376 50 2,438 37
Other 0 0 84 11 1,229 18
Age at start treatment, years‡ Artificial Real Real Real
Median 31 30 24 31§
Range 15-70 15-69 15-51 5-73
 30 2,978 46 808 49 606 81 3,202 48
30-49 2,784 43 700 42 138 19 2,646 40
 50 652 10 146 9 1  1 805 12
Age at reply questionnaire, years
Median 47 47 41 N/A
Range 23-80 24-85 24-71
Follow-up duration, years Artificial Real Real
Median 13 13 15 N/A
Range 5-44 5-44 5-44
Period of treatment start‡ Artificial Real Real Real
1964-1976 271 4 73 4 51 7 587 9
1977-1993 1,986 31 513 31 284 38 2,535 38
1994-2004 4,157 65 1,068 65 410 55 3,536 53
Disease stage
I and II N/A 1,481 90 656 88 5,719 86
III and IV 173 10 89 12 939 14
“B” symptoms present N/A 475 29 213 29 1,987 30
Initial treatment only N/A 1,472 89 659 88 5,342 80
Chemotherapy 1,235 75 523 70 4,298 65§
Alkylating agents 702 42 300 40 2,617 39
No alkylating agents 528 32 223 30 1,673 25
Radiotherapy 1,380 83 618 83 4,884 73§
Above diaphragm 1,048 63 463 62 3,453 52
Under diaphragm 331 20 155 21 1,430 21
Staging laparotomy 68 4 44 6 379 6
First- and second-line
treatment¶ N/A 182 11 86 12 1,316 20
Education level
Low 1,968 31 502 30 132 18 Not known
Middle 2,070 32 534 32 258 35
High 2,376 37 618 37 348 47
Unknown 0 0 7 1
NOTE. Due to rounding, percentages may exceed or fall short of 100%.
Abbreviation: N/A, not applicable.
External analysis: matched analysis of survivors and general population controls.
†Internal analysis: nested case-control study within survivor cohort.
‡For general population controls, data on start of artificial treatment and artificial treatment period are given.
§Age at treatment was unknown for five cases of the total 6,658. Chemotherapy details were unknown for eight cases of the total, and five were included for
external analysis. Radiotherapy details were unknown for one case of the total, included for external analysis.
¶Second-line treatment varied from radiotherapy to high-dose chemotherapy and bone marrow transplantation.
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et al,14 Tubiana et al,15 Carde et al,16 Somers et al,17 Carde et al,18 Noordijk et
al,19Alemanet al,20 Ferme´ et al,21 andThomas et al.22Administered treatment
was recorded, including chemotherapy type, number of cycles, radiotherapy
fields, and dose. In 2008, current addresses were searched for all 5,733 survi-
vors alive at last follow-up. For 3,597 survivors, a recent address was obtained
(Fig 1, CONSORT diagram).
Questionnaires
Survivors received the newly developed LSQ, which addresses issues not
available in other validated questionnaires and contains the following items:
parenthood afterHL, education,work, insurance, survivors’ health, and social
situation. Because of the sensitive nature of the questionnaire, only one re-
minder was sent after 5 weeks.
The number of children before and after HL therapy was obtained from
the following LSQ question: “How many children alive at birth have you
fathered/given birth to? Please specify the numbers before and after HL.”
Information on artificial reproductive techniques (ARTs) used was docu-
mented for children born after HL therapy. Whether patients tried to have
children afterHL therapywas evaluated on the basis of the following question:
“After first treatment forHL, did you conceive or try to conceive a pregnancy/
have you been pregnant or tried to become pregnant?” If no children were
born after HL therapy, patients were asked for their reasons for not having
children.Adoptionwas evaluatedon thebasis of the followingquestion: “After
HL, have you tried to adopt a child? If yes, did you succeed?”
Of3,597 survivors approached, 1,910 (53%) returned thequestionnaires
with a signed informed consent form. A nonresponders analysis was per-
formed to compare those who did not return the questionnaires with those
who did, and it indicated almost no differences. Respondersmore often came
from less recent trials and had slightly less often been treated with nonalkylat-
ing chemotherapy and radiotherapy above the diaphragm. Disease stage dis-
tribution was similar in responders and nonresponders.
Selection of Cases and Controls
For the external analysis (comparing survivors with general population
controls), we obtained data from the United Nations Economic Commission
for Europe (UNECE) Generations and Gender Survey, available for France
and the Netherlands.23 Patients (cases) older than age 15 years at treatment
startwith a knownnumberof children afterHLand living inFrance (n737)
or the Netherlands (n  917) were matched per stratum to controls. Strata
were defined by sex, country of residence, education level, and year of birth
(10-year groups). Four controls werematched per case, except in one stratum
in which seven cases could bematched to only three controls each. Interviews
were conducted in 2009 (cases), 2005 (French controls), and 2003 (Dutch
controls). To correct for year of interviewing (duration of follow-up), cases
were matched to controls 4 years older for France and 6 years older for the
Netherlands. After stratummatching, controls were given an artificial year of
treatment start by individually matching each case to four controls. Year of
treatment start was corrected for controls by subtracting six (theNetherlands)
or four (France). Because controls were given an artificial year of treatment
start, the expressions “children before treatment” and “children after treat-
ment”were used for both groups. Controls younger than age 15 years or older
than age 70 years at the start of fictional treatment were excluded to keep the
age range of cases and controls similar. In total, 1,654 cases were compared
with 6,414 controls (Fig 1).
Analysis of Treatment Effect
For the internal analysis (comparing survivors in different treatment
groups), we selected all survivors who replied that they had tried to have
All patients (H1 to H9)
(N = 6,658)
Questionnaires sent
(n = 3,599)
All responders
(n = 1,910)
Past onset of puberty at start of treatment
(n = 1,904)
Patients with information on parenthood
(n = 1,885)
Selection
(n = 1,654)
External analysis
Matched to general population controls
Selection
(n = 745)
All suitable for analysis
(n = 1,856)
Internal analysis
Nested case-control study
Patients who could not be matched
  From Belgium (n = 143)
)55 = n( ylatI morF  
  From Switzerland (n = 3)
  With unknown education level (n = 30)
No information on treatment (n = 6)
Patient received more than one (n = 23)
  chemotherapy regimen
No questionnaire sent
  Deceased (n = 1,418)
  Lost to follow-up (n = 719)
  Nonparticipating centers (n = 922)
No questionnaire received
)08 = n( desaeceD  
  Wrong address (n = 467)
)53 = n( lasufeR  
  No reply (n = 1,107)
Treated before age 15 years
(n = 6)
Insufficient reply to parenthood questions
(n = 19)
Did not try to have 
children after treatment
(n = 1,111)
Fig 1. Study flow diagram showing se-
lection of cases for analysis.
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children after HL treatment. Analysis was done on treatment received, not on
an intention-to-treat basis. Twenty-three survivors were excluded because
they received several chemotherapy regimens. After exclusions, 745 survivors
were suitable for internal analysis (Fig 1).
Excluding Bias From Internal Analysis
To exclude that factors associated with lower probability of post-
treatment parenthood found in the internal analysis were selected by
chance, we divided cases and matched controls from the external analysis
into six groups on the basis of these factors. Thirty-four cases and their
matched controls could not participate in the analysis because of missing
treatment details.
Definitions
Survivors given chemotherapy were grouped into those treated without
alkylating agents (doxorubicin, bleomycin, vinblastine, and dacarbazine
[ABVD]24 or epirubicin, bleomycin, vinblastine, and prednisone [EBVP]25)
and those treated with alkylating chemotherapy (mechlorethamine, vincris-
tine, procarbazine, and prednisone [MOPP]26; MOPP/ABV hybrid [MOPP/
doxorubicin, bleomycin, and vinblastine]27; or cyclophosphamide, doxo-
rubicin, vincristine, bleomycin, etoposide, procarbazine, and prednisone
[BEACOPP baseline]28). Cycles given at reduced dose were considered full
cycles. The number of cycles was used to estimate the amount of alkylating
agents administered, countingonecycleofMOPP/ABVorBEACOPPasbeing
equivalent to 0.5 cycles of MOPP. In two trials14,15 maintenance chemo-
therapywas given for 2 years: vinblastine 6 or 10mgor 6mgonce perweek for
3months alternatingwith procarbazine 150mgonce per day for 3weeks,with
a gap of 4 weeks in between. The cumulative procarbazine dose was 9 g/m2,
approximately equal to six cyclesofMOPP,andwas thereforeconsideredas six
cycles of MOPP equivalent.
Informationon smokingandeducation levelwasobtained fromtheLSQ
questionnaires. Education level was grouped into low, middle, and high: low
comprised primary school and the lower level of secondary school (corre-
sponding to International StandardClassificationofEducation [ISCED] levels
0, 1 and 229), middle comprised the higher levels of secondary school (ISCED
levels 3 and 4), and high comprised higher education and university (ISCED
levels 5 and 6).
ART meant use of intrauterine insemination, in vitro fertilization, or
intracytoplasmic sperm injection with fresh or cryopreserved semen.
Statistical Analyses
We estimated the difference in number of biologic children after treat-
ment (primary end point) between HL survivors (cases) and general popula-
tion controls. Factors associated with chances of spontaneous post-treatment
parenthood were also investigated.
Conditional logistic regression analysis was used to compare cases and
controls. Variables entered into the model to evaluate potential confounding
were age at treatment, treatment period (1964 to 1976, 1977 to 1993, 1994 to
2004), and existingbiologic childrenbefore treatment (no, yes). If the adjusted
odds ratios (aORs) for biologic children after treatment changedbymore than
10% on addition of any of these variables, they were retained in the model.
Univariable analysis of factors influencing spontaneous post-treatment
parenthood in cases was performed by using the 2 test. The multivariable
analysis was performed by using logistic regression analysis. Variables entered
were age at treatment (15 to 24, 25 to 34, or  35 years), treatment period,
clinical stage (I to II or III to IV), presence of “B” symptoms (no, yes), cycles of
alkylating chemotherapy inMOPP equivalents (no alkylating chemotherapy,
 three cycles,  three cycles MOPP equivalent), radiotherapy (above or
below the diaphragm or on the iliac and inguinal region [males]/on the iliac
region[females]), education level (low,middle,high), andpresenceofbiologic
children before treatment (no, yes). A stepwise selection procedure was used.
Results were expressed as ORs with 95%CIs. Exact binomial 95%CIs for the
proportion of male children before and after treatment were calculated. All
statistical tests were two-sided; statistical significance was defined as a P value
of less than .05. Data were stored at the EORTC data center in Brussels,
Belgium. STATA software version 10.1 (STATA, College Station, TX)
was used.
RESULTS
External Analysis
Fewer cases (513 of 1,654; 31.0%) than controls (2,288 of 6,414;
35.7%)hadat least onebiologic child after treatment (Table 2). Before
treatment, 45.7%of cases and50.2%of controlshadbiologic children.
TheOR for having children after treatment was 0.77 (95%CI, 0.68 to
0.87; P .001) for cases compared with controls. OR did not change
with correction for presence of children before treatment, age at treat-
ment, or treatment period. More cases (25 of 1,654; 1.5%) than con-
trols (56 of 6,414; 0.9%) adopted after treatment (OR, 1.78; 95% CI,
1.11 to 2.87; P .02). Thirteen additional cases attempted adoption
but without success. Three of them reported their failure was (partly)
related to their cancer history.
Females andmales had different outcomes. Among females, sig-
nificantly fewer cases (274 of 839; 32.7%) than controls (1,263 of
3,248;38.9%)hadbiologic childrenafter treatment.Amongmales, the
difference between cases and controlswas smaller: 239 of 815 (29.3%)
of cases versus 1,025 of 3,166 (32.4%) of controls. The aOR was 0.64
(95% CI, 0.52 to 0.77; P  .001) for females corrected for age at
treatment start;ORwas 0.84 (95%CI, 0.70 to 1.00;P .06) formales.
We investigated the importanceofalreadyhavingchildrenbefore
treatment. Of 898 cases who were childless before treatment, 539
(60.0%) tried to have children and 419 (46.7%) succeeded compared
with 1,575 of 3,196 (49.3%) of childless controls (OR, 0.87; 95% CI,
0.74 to 1.01; P  .08). Among survivors with children before treat-
ment, the difference between cases and controls was more marked:
127 of 756 cases (16.8%) attempted post-treatment parenthood and
94 (12.4%) succeeded compared with 713 (22.2%) of 3,218 controls
(OR, 0.49; 95%CI, 0.38 to 0.63; P .001). Results were similar when
all cases (262; 15.8%) and controls (1,097; 17.1%) older than age 45
years at treatment were excluded.
Looking at cases only, 666 attemptedpost-treatmentparenthood
and 513 (77%) succeeded (Table 3). Chances of success did not differ
between those with and those without children before treatment.
Chances of success were also similar between males and females, but
males used ARTs far more often. Approximately 40% of those who
were childless butmore than 80%of those with children before treat-
ment did not try to have children after treatment. Reasons for survi-
vors’ decision to refrain from having children are listed in Table 4.
Among those with children before treatment, “family was already
completed” was the most frequent reply (82%). In those who were
Table 2. Children Before and After Treatment in Cases and Controls
(external analysis)
Before Treatment
No Children
After Treatment
Children After
Treatment
TotalNo. % No. %
Cases
No children 479 53.3 419 46.7 898
Children 662 87.6 94 12.4 756
Controls
No children 1,621 50.7 1,575 49.3 3,196
Children 2,505 77.8 713 22.2 3,218
Parenthood After Hodgkin Lymphoma
www.jco.org © 2012 by American Society of Clinical Oncology 3857
Downloaded from ascopubs.org by Radboud University Nijmegen on January 26, 2020 from 131.174.248.154
Copyright © 2020 American Society of Clinical Oncology. All rights reserved.
childless, “personal decision” (28%), “being single” (28%), and “I
plan to have children later on” (25%) were the most frequent expla-
nations for the decision not to have children until now. Survivors
could choose several reasons, but the large majority (84%) expressed
one reasononly, independently of sex (89% inmales, 78% in females)
for having (86%) or not having (80%) children before treatment.
Internal Analysis
Amongmales attempting post-treatment parenthood, 63% (217
of 345) succeeded spontaneously, and a further 15% (49 of 345)
succeeded with the help of ARTs (Table 5). Among females, these
figures were 74% (295 of 400) and only 2% (eight of 400) with ARTs.
In males, age 35 years or older (OR, 0.16; P .001) and second-line
treatment (OR, 0.10;P .001)were associatedwith lower probability
of spontaneous post-treatment parenthood. A strong dose-response
relationship was found with dose of alkylating chemotherapy admin-
istered: the ORwas 0.34 (P .003) for treatment with less than three
MOPP-equivalent cycles of alkylating chemotherapy compared with
an OR of 0.04 (P .001) for treatment with three or more MOPP-
equivalent cycles. In females, lower probability of post-treatment par-
enthoodwasassociatedwithage35yearsorolder (OR,0.13;P .001),
treatment with three or more MOPP-equivalent cycles of alkylating
chemotherapy (OR, 0.51; P .01), second-line treatment (OR, 0.27;
P .001), and high education level (OR, 0.58; P .03).
Excluding Bias From Internal Analysis
ORs for all biologic children after treatment for cases were con-
sistently lower in females than in males (Fig 2) compared with con-
trols.Theywere also lowerwhenmore aggressive treatmentwas given.
Sex Ratio of Children
Among 1,662 children born before treatment to 820 cases (inter-
nal control), the female:male ratio was 1.000:1.062 (proportion of
boys, 0.531; 95% CI, 0.503 to 0.558). Among 995 children born after
treatment to 570 cases, the ratiowas similarwith 1.000:1.033 (propor-
tion of boys, 0.516; 95%CI, 0.483 to 0.550). Inmale cases, the before-
treatment ratio was 1.000:1.074 (864 children; 423 males; proportion
of boys, 0.537; 95% CI, 0.499 to 0.575) and that after treatment was
1.000:1.073 (476 children; 264males; proportion of boys, 0.537; 95%
CI, 0.489 to 0.584).
DISCUSSION
In a large cohort of long-term HL survivors, we observed survivors
had significantly fewer children after treatment than general popula-
tion controls. This difference was significant only in females and
among those who already had biologic children before treatment.
When further investigating this remarkable finding in survivors with
Table 3. Parenthood in Cases From the External Analysis: Outcome According to Sex and Biological Children Before Treatment
Outcome Sex
Attempt
No Children After Treatment Children After Treatment
No Attempt Failure ART Spontaneous
No. % No. % No. % No. % No. %
No children before treatment Male 237 56 188 44 48 20 36 15 153 65
Female 302 64 171 36 72 24 5 2 225 75
Children before treatment Male 67 17 323 83 17 25 11 16 39 58
Female 60 16 306 84 16 27 0 44 73
Total 666 40 988 60 153 23 52 8 461 69
NOTE. Percentages in the Failure column and beyond are calculated within the group who attempted.
ART (assisted reproductive techniques) includes intrauterine insemination, in vitro fertilization, or intracytoplasmic sperm injection with fresh or cryopreserved semen.
Table 4. Reasons Not to Have Children After Treatment in Cases Who Did Not Try and Did Not Have Children After Treatment (cases from the external analysis)
Reason
Males
(n  511)
Females
(n  477)
Children Before Treatment
All
(N  988)
No
(n  359)
Yes
(n  629)
No. % No. % No. % No. % No. %
Family completed (children before HL) 288 57 230 48 4† 1 514 82 518 53
Personal decision 66 13 105 22 102 28 69 11 171 17
Medical reasons 22 4 35 7 36 10 21 3 57 6
Plan to have children later on 45 9 44 9 88 25 1  1 89 9
Being single 60 12 46 10 101 28 5 1 106 11
No particular reasons 23 5 22 5 30 8 15 2 45 5
Other 33 6 38 8 33 9 38 6 71 7
No response given 18 4 34 7 22 6 30 5 52 5
Abbreviation: HL, Hodgkin lymphoma.
Patients could give more than one reason.
†Probably due to presence of biological children from partner or a misinterpretation.
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Table 5. Multivariable Analysis of Factors Influencing Survivors’ Odds of Having Children Without ART (internal analysis)
Factor
Biological
Children
Without
ART
No
Biological
Children
Spont-
aneously
No
Biological
Children
Biological
Children
With
ART† Total
2 P‡
Model With All
Variables Adjusted Final Model Adjusted
No. % No. % No. % No. % No. % OR 95% CI P‡ OR 95% CI P‡
Males 217 63 128 37 79 23 49 14 345
Age at start of treatment,
years
15-24 89 41 38 27 20 25 18 37 127 37  .001 1.00 1.00§
25-34 112 52 66 52 39 49 27 55 178 52 0.52 0.26 to 1.02 .06
 35 16 7 24 19 20 25 4 8 40 12 0.09 0.03 to 0.27  .001 0.16 0.07 to 0.36  .001
Period of treatment start
1964-1976 17 8 5 4 5 6 0 22 6 .29 1.00 —
1977-1993 89 41 57 45 32 41 25 51 146 42 1.33 0.34 to 5.16 .74
1994-2004 111 51 66 52 42 53 24 49 177 51 1.26 0.32 to 4.95 .65
Disease stage
I and II 207 95 92 72 57 72 35 71 299 87  .001 1.00 —
III and IV 10 5 36 28 22 28 14 29 46 13 1.30 0.42 to 4.03 .65
B-symptoms
Absent 157 72 76 59 45 57 31 63 233 68 .11 1.00 —
Present 59 27 52 41 34 43 18 37 111 32 0.79 0.42 to 1.51 .48
Unknown 1  1 0 0 0 1
Initial treatment only 203 96 93 73 57 72 36 73 296 86
Chemotherapy
No alkylating agents 80 37 12 9 11 14 1 2 92 27 1.00 1.00
Alkylating agents 64 29 75 59 40 51 35 71 139 40
 3 cycles MOPP
equivalent 42 19 21 16 11 14 10 20 63 18  .001 0.37 0.17 to 0.82 .01 0.34 0.16 to 0.70 .003
 3 cycles MOPP
equivalent 22 10 54 42 29 37 25 51 76 22 0.04 0.02 to 0.10  .001 0.04 0.02 to 0.09  .001
Radiotherapy
Above diaphragm 149 67 79 62 49 62 30 61 228 66 .03 1.00 —
Below diaphragm 47 22 15 12 10 13 5 10 62 18 1.09 0.47 to 2.55 .84
Iliac and inguinal region 12 6 16 13 8 10 8 16 28 8 0.60 0.18 to 2.02 .41
First- and second-line
treatment¶ 14 6 35 27 22 28 13 27 49 14  .001 0.10 0.04 to 0.24  .001 0.10 0.04 to 0.23  .001
Education level
Low 45 21 21 16 14 17 7 14 66 19 .17 1.00 —
Middle 77 36 49 38 32 41 17 35 126 37 0.62 0.26 to 1.48 .29
High 95 44 56 44 31 39 25 51 151 44 0.55 0.23 to 1.30 .17
Unknown 0 2 2 2 3 0 2 1
Children before treatment
No 168 77 97 76 58 83 39 80 665 89 .68 1.00 —
Yes 49 23 31 24 21 27 10 20 80 23 1.23 0.58 to 2.63 .59
Females 295 74 105 26 97 24 8 2 400
Age at start of treatment,
years
15-24 172 58 46 44 42 43 4 50 218 55 .001 1.00 1.00§
25-34 118 40 49 47 45 46 4 50 167 42 0.73 0.94 to 1.29 .28
 35 5 2 10 10 10 10 0 15 4 0.11 0.03 to 0.38  .001 0.13 0.04 to 0.43  .001
Period of treatment start
1964-1976 26 9 3 3 3 3 0 29 7 .06 1.00 —
1977-1993 105 36 33 31 28 29 5 63 138 35 0.72 0.17 to 2.96 .65
1994-2004 164 56 69 66 66 68 3 38 233 58 0.38 0.09 to 1.53 .17
Disease stage
I and II 272 92 85 81 78 80 7 88 357 89 .005 1.00 —
III and IV 23 8 20 19 19 20 1 13 43 11 0.47 0.16 to 1.35 .16
B-symptoms
Absent 222 75 67 64 63 65 4 50 289 72 .12 1.00 —
Present 68 23 34 32 30 31 4 50 102 26 0.65 0.36 to 1.14 .13
Unknown 5 2 4 4 4 4 0 9 2
(continued on following page)
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children before treatment, we found the main difference was in the
group who decided to refrain from having children after treatment.
This suggests at least part of the parenthood outcome inHL survivors
was the result of a personal decision rather than a biologic reason.
Several factors were associatedwith reduced probability of spon-
taneous success among survivors who attempted post-treatment par-
enthood: age 35 years at treatment, alkylating chemotherapy, and
second-line treatment. The aORs for post-treatment spontaneous
Table 5. Multivariable Analysis of Factors Influencing Survivors’ Odds of Having Children Without ART (internal analysis) (continued)
Factor
Biological
Children
Without
ART
No
Biological
Children
Spont-
aneously
No
Biological
Children
Biological
Children
With
ART† Total
2 P‡
Model With All
Variables Adjusted Final Model Adjusted
No. % No. % No. % No. % No. % OR 95% CI P‡ OR 95% CI P‡
Initial treatment only 276 94 87 83 80 83 7 88 363 91
Chemotherapy
No alkylating agents 98 33 33 31 29 30 4 50 131 33 1.00 1.00§
Alkylating agents 119 40 42 40 41 42 1 13 161 40
 3 cycles MOPP
equivalent 57 19 15 14 15 15 0 72 18 .18 1.24 0.60 to 2.56 .56
 3 cycles MOPP
equivalent 62 21 27 26 26 6 1 13 89 22 0.69 0.31 to 1.50 .35 0.51 0.30 to 0.87 .01
Radiotherapy
Above diaphragm 213 72 67 64 63 65 4 50 280 70 .29 1.00 —
Below diaphragm 56 19 15 14 12 12 3 38 71 18 0.92 0.44 to 1.89 .82
Iliac region 10 3 8 8 8 8 0 18 5 0.93 0.25 to 3.41 .91
First- and second-line
treatment¶ 19 6 18 17 17 17 1 13 37 9 .005 0.22 0.10 to 0.52  .001 0.27 0.12 to 0.57  .001
Education level
Low 53 18 22 21 21 12 1 13 66 17 .45 1.00 1.00§
Middle 103 35 29 28 27 28 2 25 132 33 0.94 0.41 to 2.16 .88
High 136 46 61 58 56 58 5 63 197 49 0.59 0.27 to 1.31 .20 0.58 0.36 to 0.93 .03
Unknown 3 1 2 2 2 2 0 5 1
Children before treatment
No 245 83 85 81 77 79 8 100 330 83 .30 1.00 —
Yes 50 17 20 19 20 21 0 70 18 1.15 0.56 to 2.35 .71
NOTE. Due to rounding, percentages may exceed or fall short of 100%. OR (odds ratio) for iliac and/or inguinal region radiotherapy are taken together. Radiotherapy
under the diaphragm was analyzed exclusive of iliac and inguinal radiotherapy.
Abbreviations: ART, assisted reproductive technique; MOPP, mechlorethamine, vincristine, procarbazine, and prednisone.
The column labeled “No Biological Children Spontaneously” is the sum of the “No Biological Children” and “Biological Children With ART” columns.
†ART includes intrauterine insemination, in vitro fertilization or intracytoplasmic sperm injection with fresh or cryopreserved semen.
‡For 2 testing, the fifth and seventh columns were analyzed separately against each other and the first column, so test results are for children conceived
spontaneously (without ART) versus biological children conceived with ART and versus failure to conceive children. For logistic regression analysis, the fifth and
seventh columns were taken together, see third column, and analyzed against the first column. ORs provided are ORs for having biological children without ART.
§In the final model for both males and females, age 15-24 and 25-34 years were taken together as the reference category, as were no alkylating chemotherapy
and  three cycles of MOPP equivalent, and low and middle education level in the final model for females.
¶Second-line treatment varying from radiotherapy to high-dose chemotherapy and bone marrow transplantation.
Women, second-line treatment
Women, ≥ 3 cycles MOPPeq
Men, ≥ 3 cycles MOPPeq
Women, < 3 cycles MOPPeq
Men, < 3 cycles MOPPeq
Men, second-line treatment
 75 290
Patients
(n)
Controls
(n)
 173 678
 164 632
 569 2,192
 532 2,062
Odds Ratio (95% CI)
0.0 0.5 1.0 1.5
 107 424
Fig 2. Odds ratios for having biologic
children after treatment, in cases com-
pared with general population controls.
MOPP, mechlorethamine, vincristine,
procarbazine, and prednisone; MOPPeq,
cycles of alkylating chemotherapy in
MOPP equivalents.
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parenthood associated with alkylating chemotherapy were extremely
low, especially inmen (aOR, 0.04 if alkylating chemotherapy dosewas
three or more cycles of MOPP equivalent), demonstrating greater
impactof treatmenton fertility inmenthan inwomen.Men,however,
can compensate for loss of fertility by using cryopreserved semen;
women have no such option readily available. This explains why the
probability of biologic children (with or without ARTs) was reduced
in female HL survivors.
Comparedwith controls, female andmaleHL survivors hadORs
for having children after treatment similar to those reported byCvan-
carova et al10 in combined lymphoma and leukemia survivors:ORs of
0.61 and0.88, respectively, comparedwithORsof 0.64 and0.84 inour
series. They also found a remarkably reduced reproduction rate in
survivors with children before treatment but gave no explanation.
Our study is by far the largest and the only one with general
population controls performed among HL survivors. It is unique in
presenting data on motivations for parenthood choices. Little is
known about motivation for parenthood after cancer treatment.
There are several reasonswhy survivors forgobecoming aparent: they
might fear dying prematurely or suffering cancer treatment–related
health complaints.Theymight alsobe afraid that cancer treatmenthas
damaged their gametes and reproductive system, leading to more
pregnancy complications and handicaps in offspring. Another reason
might be fear of increased cancer risk in offspring. However, we
considered it unethical to address questions like fear of carcinogenesis
by mail and therefore did not investigate this in detail. One-fifth of
patients did not have children after treatment because of a personal
decision, and survivors considered their family complete more often
thandid controls at the samepoint in their lives. Schover et al30,31 have
analyzed in male cancer survivors that survivors’ perceptions play an
important role, which was also suggested by our results. They found
that 6% of cancer survivors who were childless before treatment have
their wish for future children decreased by cancer versus 29% of
survivors who had children before treatment.
Evidence has been published of a reversed sex ratio in offspring of
male childhood cancer survivors compared with their siblings with an
excess of female offspring.32 Reduced testosterone levels and Leydig cell
dysfunction were considered causative factors.33 In HL survivors, there
has been limited evidence ofmild Leydig cell dysfunction.34,35We found
nodifference insexratiobeforeandafter treatment: the female:male ratio
of0.93observedaftertreatmentwasclosetothenormalpopulationvalues
of 0.94 to 0.95,36-38 in agreementwith previous findings.39-41
Of the 3,599 questionnaires sent, 1,910 (53%) were completed.
Of 6,658 patients initially included in the trials, 1,498 (22%) died, 922
(14%)were included in centers that did not participate in this survey,
and 719 (11%) were lost to follow-up. The explanation for the seem-
ingly lowresponseof53%lies inwhat is alsooneof the strengthsof this
study: its scope.Muchhappenedbetween trial inclusionbetween1964
and 2004 and the start of this survey: physicians moved away or died,
hospitals merged, and whole departments disappeared, hampering
the tracing back of many patients treated in the past. Because of
privacy laws, we were not allowed to track down patients directly but
were required to do our tracking via their original treating physician.
Manynonresponderswere survivors forwhomnocorrect addresswas
found by their former physicians.
Overall, 25%of the control group remained childless; it was 23%
(752 of 3,248) in women. This is quite high, indicating a potentially
increasedrateof subfertility.AmongDutchwomenborn in1945,11%
remained childless; for women born in 1960, it was 17%, and for
womenborn in 1975, it was 20%.42 In France, these figures are 10% in
women born in 1950 and 15% in those born in 1980.43 However, our
control group does not appear to be subfertile when keeping inmind
that controlswere bornbetween1923 and1982but thedistributionof
year of birth was skewed toward the younger years. Higher education
levels were also over-represented among HL survivors and thus
among ourmatched controls (who remained childlessmore often42).
Follow-up in our studywas long-termbut still incomplete, suggesting
that participants might start a family in the future.
Anotherpotential sourceofbias couldbeconfoundingbymarital
status. Two studies44,45 reported that cancer survivors are less often
married, which might lead to smaller chances of starting a family. In
our study, more than 80% of survivors were currently married or
living together, a high rate that limits the possible influence of this
potential source of bias.
We documented that nonresponders had more likely been treated
withnonalkylatingchemotherapyandradiotherapyabovethediaphragm
only. This may contribute to an underestimation of parenthood proba-
bility in our survivors. However, given that our results found no differ-
ences between patients and controls without children before treatment,
this potential underestimation is unlikely to influence our conclusions.
In conclusion, survivors of HL had significantly fewer children
after treatment than did general population controls. The difference
concerned only patients who already had children before treatment
and was larger in females than in males. Both psychological and
treatment factors contributed. Finally, three-quarters of survivors
who attempted post-treatment parenthood succeeded.
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Art of Oncology Volume 2
Art of Oncology Volume 2: Honest and Compassionate Responses to the Daily Struggles of People Living With Cancer,
edited by Charles L. Loprinzi, MD, is a collection of 34 brief articles that first appeared in Journal of Clinical Oncology. The
essays address issues related to end-of-life care, symptom control, ethics, and communication with patients.
In these heartfelt pieces, doctors reveal how they respond to the personal needs of people with cancer; how to be honest
with patients about their condition; how to be realistic but simultaneously hopeful; and how to answer the difficult question
of “How much time do I have left?”
Art of Oncology Volume 2 is available only as a Kindle e-book and can be purchased for $6.99
at jco.org/kindle2.
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